US › Healthcare

Bioatla Inc (BCAB)

US · Healthcare · Biotechnology

$3.35+2.76%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-6.3M
Profit YoY
+58.6%
EPS
$-4.22

Key statistics

Market cap
$5.5M
Forward P/E
0.0
P/B
2.68
Book value
$-22.48
EPS (TTM)
$-41.69
52-week high
$71.50
52-week low
$3.12
50-day MA
$3.70
200-day MA
$16.00
Beta
0.75

Analyst view

Analysts rate Bioatla Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $10.00.

Shareholding

Insiders
5.46%
Institutions
22.40%

Largest institutional holders

FundStake
Millennium Management LLC3.32%
Vanguard Capital Management, LLC1.99%
Acadian Asset Management LLC1.49%
Geode Capital Management, LLC0.83%
Deutsche Bank AG0.63%
Renaissance Technologies Corp0.62%
BlackRock Inc0.58%
Citadel Advisors Llc0.53%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bioatla Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.